Respiratory syncytial virus vaccine - Pierre FabreAlternative Names: BBG2Na; F50077; J002X; L0077
Latest Information Update: 19 Oct 2005
At a glance
- Originator Pierre Fabre
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Respiratory syncytial virus infections